Jazz Pharmaceuticals Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Jazz Pharmaceuticals stock.
View analyst ratings for Jazz Pharmaceuticals or view top-rated stocks.

11 Wall Street analysts have issued 12 month target prices for Jazz Pharmaceuticals' shares. Their JAZZ stock forecasts range from $174.00 to $225.00. On average, they anticipate Jazz Pharmaceuticals' share price to reach $204.14 in the next year. This suggests a possible upside of 33.0% from the stock's current price.
View analysts' price targets for Jazz Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Jazz Pharmaceuticals' stock was trading at $127.40 on January 1st, 2022. Since then, JAZZ stock has increased by 20.5% and is now trading at $153.49.
View the best growth stocks for 2022 here.

Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Jazz Pharmaceuticals.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced its quarterly earnings results on Wednesday, May, 4th. The specialty pharmaceutical company reported $3.13 EPS for the quarter, topping analysts' consensus estimates of $3.00 by $0.13. The specialty pharmaceutical company had revenue of $813.72 million for the quarter, compared to the consensus estimate of $853.73 million. Jazz Pharmaceuticals had a positive trailing twelve-month return on equity of 22.45% and a negative net margin of 13.63%. The business's revenue for the quarter was up 33.9% compared to the same quarter last year. During the same period in the prior year, the business earned $3.42 EPS.
View Jazz Pharmaceuticals' earnings history.

Jazz Pharmaceuticals issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.50 billion-$3.70 billion, compared to the consensus revenue estimate of $3.58 billion.

60 employees have rated Jazz Pharmaceuticals CEO Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among Jazz Pharmaceuticals' employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Jazz Pharmaceuticals include Johnson & Johnson (JNJ), Eli Lilly and (LLY), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Perrigo (PRGO), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR) and Omeros (OMER).
View all of JAZZ's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Jazz Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.36%), Vanguard Group Inc. (8.99%), JPMorgan Chase & Co. (5.28%), Wellington Management Group LLP (4.21%), State Street Corp (3.76%) and LSV Asset Management (2.90%). Company insiders that own Jazz Pharmaceuticals stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Catherine A Sohn, Elmar Schnee, Finbar Larkin, James E Flynn, Kenneth W O'keefe, Kim Sablich, Mark Douglas Smith, Michael Patrick Miller, Neena M Patil, Patricia Carr, Patrick G Enright, Paul L Berns, Paul Treacy, Samantha Pearce and Seamus Mulligan.
View institutional ownership trends for Jazz Pharmaceuticals.

JAZZ stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Polar Capital Holdings Plc, Goldman Sachs Group Inc., Renaissance Technologies LLC, Victory Capital Management Inc., Assenagon Asset Management S.A., Bellevue Group AG, and Rhenman & Partners Asset Management AB. Company insiders that have sold Jazz Pharmaceuticals company stock in the last two years include Anne Oriordan, Bruce C Cozadd, Elmar Schnee, Finbar Larkin, Kim Sablich, Mark Douglas Smith, Neena M Patil, Patricia Carr, Patrick G Enright, Paul L Berns, and Samantha Pearce.
View insider buying and selling activity for Jazz Pharmaceuticals or view top insider-selling stocks.

JAZZ stock was bought by a variety of institutional investors in the last quarter, including Atika Capital Management LLC, Wellington Management Group LLP, Sumitomo Mitsui Trust Holdings Inc., Woodline Partners LP, Great Point Partners LLC, Loomis Sayles & Co. L P, JPMorgan Chase & Co., and Braun Stacey Associates Inc..
View insider buying and selling activity for Jazz Pharmaceuticals or or view top insider-buying stocks.

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of JAZZ stock can currently be purchased for approximately $153.49.

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a market capitalization of $9.58 billion and generates $3.09 billion in revenue each year. The specialty pharmaceutical company earns $-329.67 million in net income (profit) each year or ($7.510010) on an earnings per share basis.

Jazz Pharmaceuticals employs 3,200 workers across the globe.

Jazz Pharmaceuticals was founded in 2003.

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The official website for Jazz Pharmaceuticals is www.jazzpharma.com. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at [email protected], or via fax at 353-1634-7850.